Immunome completes Morphimmune merger, $125M PIPE, Q3 net loss $4M

Immunome Inc.

Completed merger with Morphimmune; concurrent $125M oversubscribed PIPE from Enavate Sciences, EcoR1 Capital, Redmile, Janus Henderson, Avidity, Woodline.
Clay B. Siegall (ex-Seagen CEO) appointed Chairman & CEO; Bob Lechleider as CMO; Jean-Jacques Bienaimé (ex-BioMarin CEO) to board.
Q3 collaboration revenue $4M from AbbVie; R&D and G&A each $4M; net loss $4M ($0.36 per share); cash $91M as of Sept 30.
Cash runway extended into Q1 2026; expect IMM-ONC-01 IND guidance Q1 2024; 177Lu-FAP IND submission Q1 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immunome Inc. reported the third quarter ended September 30, 2023 results: revenue $4 million, net income Net loss ... was $4 million, or $(0.36) per share, EPS $(0.36) per share.

Period: the third quarter ended September 30, 2023
Revenue: $4 million
Net income: Net loss ... was $4 million, or $(0.36) per share
EPS: $(0.36) per share
Result: reported results

Exact text from the filing

in Q1 2025. Financial Highlights · Collaboration Revenue: Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended September 30, 2023 was $4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2023 were $4 million. · General and administrative (G&A) expenses: G&A expenses

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.